1,3-Oxazol-2(5H)-one → 3-{3-Cyano-4-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}oxazolidin-2-one
반응식
Br[C:2]1[CH:3]=[CH:4][C:5]([C:10]([N:12]2[CH2:17][CH2:16][N:15]([C:18]3[C:23]([CH3:24])=[CH:22][C:21]([CH3:25])=[CH:20][N:19]=3)[CH2:14][CH2:13]2)=[O:11])=[C:6]([CH:9]=1)[C:7]#[N:8].[O:26]1[CH2:30][CH:29]=[N:28][C:27]1=[O:31]>>[C:7]([C:6]1[CH:9]=[C:2]([N:28]2[CH2:29][CH2:30][O:26][C:27]2=[O:31])[CH:3]=[CH:4][C:5]=1[C:10]([N:12]1[CH2:17][CH2:16][N:15]([C:18]2[C:23]([CH3:24])=[CH:22][C:21]([CH3:25])=[CH:20][N:19]=2)[CH2:14][CH2:13]1)=[O:11])#[N:8]참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 110 and using 5-bromo-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]benzonitrile (399 mg) described in Preparation Example 193 and oxazolin-2-one (104 mg), the title compound (327 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 110